Key Takeaways:
Amgen's dazodalibep met the primary endpoint of the Phase 3 OASIZ 301 study in systemic Sjögren's disease, cutting disease activity at week 48 in a condition with no FDA-approved therapy.
"The results mark an important step forward for people living with Sjögren's disease, a condition with significant unmet need and no approved systemic treatment options," Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen, said.
The Thousand Oaks, California-based company said the trial, which enrolled roughly 621 adults with moderate-to-severe systemic disease activity, showed statistically significant and clinically meaningful improvement on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) at week 48. ESSDAI scores systemic disease activity across organ systems. Amgen said improvements appeared as early as week 4 and held through week 48. Key secondary endpoints covered dryness, tender and swollen joints, fatigue, and an ESSDAI response defined as a drop of at least 5 points from baseline. Amgen did not disclose the magnitude of the ESSDAI change or the p-value in the topline release, saying detailed data will be presented at an upcoming medical meeting.
Dazodalibep is a CD40L antagonist fusion protein that blocks interactions between T cells, B cells and other antigen-presenting cells. It is the most advanced asset in a CD40L class that has drawn interest across autoimmune drug development, where rivals have pursued the same pathway. Amgen is running OASIZ 303 in patients with high symptom burden and low systemic disease activity, a study expected to complete in the fourth quarter of 2026, plus OASIZ 304, an open-label long-term extension tracking safety in eligible patients from both trials.
Safety in OASIZ 301 was manageable. The most common adverse events reported at 5% or higher and more often on dazodalibep than placebo were nasopharyngitis, urinary tract infection, hypertension and infusion-related reactions, generally mild to moderate. Discontinuations for adverse events were low and balanced across arms, and Amgen reported no imbalance in thromboembolic events or opportunistic infections — a point of scrutiny for the CD40L class after earlier programs raised clotting concerns.
Sjögren's disease is the second most common autoimmune rheumatic disease, yet it has no approved disease-modifying therapy. Patients contend with persistent dryness, fatigue and chronic pain, and a subset develops major organ involvement, neuropathy or elevated lymphoma risk. "Patients with Sjogren's disease contend with debilitating symptoms and systemic manifestations for which no approved disease-modifying therapy exists," Ghaith Noaiseh, associate professor of medicine at the University of Kansas Medical Center and lead investigator of the study, said.
Amgen shares have rallied 27.9% year to date, against an 8% gain for the industry, according to Zacks Investment Research. The company has not disclosed a regulatory submission timeline for dazodalibep, leaving the filing date as the next hard checkpoint for investors. Amgen's late-stage pipeline also includes olpasiran for atherosclerotic cardiovascular disease, xaluritamig for metastatic castration-resistant prostate cancer and daxdilimab for primary discoid lupus erythematosus, alongside MariTide in obesity and type 2 diabetes.
For holders, the readout removes the binary risk on Amgen's lead immunology asset and shifts the debate to filing strategy and commercial scale in a market with no incumbent to displace. The next catalyst is the OASIZ 303 completion in the fourth quarter of 2026, which tests whether dazodalibep works in the larger, symptom-driven patient group where dryness and fatigue — not organ involvement — drive treatment demand.
This article is for informational purposes only and does not constitute investment advice.
